186 related articles for article (PubMed ID: 30076764)
1. Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling.
Chang MT; Lee SP; Fang CY; Hsieh PL; Liao YW; Lu MY; Tsai LL; Yu CC; Liu CM
Environ Toxicol; 2018 Nov; 33(11):1105-1112. PubMed ID: 30076764
[TBL] [Abstract][Full Text] [Related]
2. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction.
Huang JS; Yao CJ; Chuang SE; Yeh CT; Lee LM; Chen RM; Chao WJ; Whang-Peng J; Lai GM
BMC Cancer; 2016 Mar; 16():245. PubMed ID: 27012679
[TBL] [Abstract][Full Text] [Related]
3. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
4. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
[TBL] [Abstract][Full Text] [Related]
5. 2-O-Methylmagnolol Induces Apoptosis and Inhibits IL-6/STAT3 Signaling in Oral Squamous Cell Carcinoma.
Wang TH; Fang JY; Wu SJ; Liu YW; Chan CW; Chuang SY; Chen CY
Cell Physiol Biochem; 2018; 50(3):883-892. PubMed ID: 30355952
[TBL] [Abstract][Full Text] [Related]
6. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells.
Ji N; Jiang L; Deng P; Xu H; Chen F; Liu J; Li J; Liao G; Zeng X; Lin Y; Feng M; Li L; Chen Q
J Oral Pathol Med; 2017 Mar; 46(3):201-207. PubMed ID: 27465776
[TBL] [Abstract][Full Text] [Related]
8. Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas.
Peng CY; Yu CC; Huang CC; Liao YW; Hsieh PL; Chu PM; Yu CH; Lin SS
J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):51-57. PubMed ID: 33551310
[TBL] [Abstract][Full Text] [Related]
9. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
[TBL] [Abstract][Full Text] [Related]
10. Investigation of ovatodiolide, a macrocyclic diterpenoid, as a potential inhibitor of oral cancer stem-like cells properties via the inhibition of the JAK2/STAT3/JARID1B signal circuit.
Lin CS; Bamodu OA; Kuo KT; Huang CM; Liu SC; Wang CH; Tzeng YM; Chao TY; Yeh CT
Phytomedicine; 2018 Jul; 46():93-103. PubMed ID: 30097127
[TBL] [Abstract][Full Text] [Related]
11. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Lai IC; Shih PH; Yao CJ; Yeh CT; Wang-Peng J; Lui TN; Chuang SE; Hu TS; Lai TY; Lai GM
PLoS One; 2015; 10(3):e0114830. PubMed ID: 25763821
[TBL] [Abstract][Full Text] [Related]
12. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
[TBL] [Abstract][Full Text] [Related]
13. GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma.
Rodrigues MFSD; Miguita L; De Andrade NP; Heguedusch D; Rodini CO; Moyses RA; Toporcov TN; Gama RR; Tajara EE; Nunes FD
Int J Oncol; 2018 Dec; 53(6):2458-2472. PubMed ID: 30272273
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft.
Cho JH; Jeon YJ; Park SM; Shin JC; Lee TH; Jung S; Park H; Ryu J; Chen H; Dong Z; Shim JH; Chae JI
Biomaterials; 2015; 53():274-84. PubMed ID: 25890726
[TBL] [Abstract][Full Text] [Related]
15. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.
Wang X; Beitler JJ; Wang H; Lee MJ; Huang W; Koenig L; Nannapaneni S; Amin AR; Bonner M; Shin HJ; Chen ZG; Arbiser JL; Shin DM
PLoS One; 2014; 9(2):e86369. PubMed ID: 24586249
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
18. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
19. Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis.
Yu CC; Chen PN; Peng CY; Yu CH; Chou MY
Oncotarget; 2016 Apr; 7(15):20180-92. PubMed ID: 26933999
[TBL] [Abstract][Full Text] [Related]
20. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells.
Ponnurangam S; Mammen JM; Ramalingam S; He Z; Zhang Y; Umar S; Subramaniam D; Anant S
Mol Cancer Ther; 2012 Apr; 11(4):963-72. PubMed ID: 22319203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
